Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 in Participants With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year.~* HbA1c of ≥7.0 and ≤9.5%.~* Use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin.~* Use insulin glargine, insulin detemir, insulin degludec, or neutral protamine Hagedorn (NPH) insulin as basal insulin.~Exclusion Criteria:~* Have used other antihyperglycemic medications or therapies (inhaled, oral or injectable) within 90-days of screening.~* Have had more than 1 severe hypoglycemic episode within 6 months of screening.~* Have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening.~* Have clinically significant gastrointestinal disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY900014 (Type: EXPERIMENTAL): LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
- Insulin Lispro (Humalog) (Type: ACTIVE_COMPARATOR): Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
- LY900014 Postmeal (Open Label) (Type: EXPERIMENTAL): LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
- LY900014 - Maximum Extended Enrollment (MEE) (Type: EXPERIMENTAL): LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
- Insulin Lispro (Humalog)-MEE (Type: ACTIVE_COMPARATOR): Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
- LY900014 Postmeal (Open Label)-MEE (Type: EXPERIMENTAL): LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete